Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma
Crossref DOI link: https://doi.org/10.1371/journal.pone.0184423
Published Online: 2017-09-08
Update policy: https://doi.org/10.1371/journal.pone.corrections_policy
Amzal, Billy
Fu, Shuai
Meng, Jie
Lister, Johanna http://orcid.org/0000-0002-7166-4758
Karcher, Helene
Version of Record valid from 2017-09-08